Literature DB >> 16309167

Osteoprotegerin is expressed in colon carcinoma cells.

Ingvild Pettersen1, Wenche Bakkelund, Bård Smedsrød, Baldur Sveinbjørnsson.   

Abstract

BACKGROUND: Osteoprotegerin (OPG), a soluble member of the tumor necrosis factor family, is produced by various cell types and tissues and plays a key role in the physiological regulation of osteoclast differentiation and activity. Also, OPG is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing factor (TRAIL). In the present study we investigated whether the human colon cancer cell lines HT-29 and SW-480 produce and secrete OPG in vitro.
MATERIALS AND METHODS: Expression of OPG mRNA was examined by RT-PCR. OPG protein was analysed by ELISA assay and immunostaining methods. The effect of OPG secretion on TRAIL-mediated apoptosis was also investigated.
RESULTS: By RT-PCR, it was demonstrated that mRNA transcripts for OPG were produced by both cell lines. By ELISA analysis, OPG was detected in the culture medium; and treatment of cells with proinflammatory cytokines TNF-alpha and IL-1beta increased OPG secretion significantly. Tumor xenografts in nude mice also were shown to express OPG by immunohistochemistry. When RANKL, which selectively binds OPG, was added to cell cultures along with recombinant TRAIL, apoptosis was shown to increase significantly.
CONCLUSION: These data indicate that OPG may be involved in tumorigenesis and the progression of colon cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16309167

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Osteoprotegerin (OPG) and related proteins (RANK, RANKL and TRAIL) in thyroid disease.

Authors:  Sumit K Sood; Sabapathy Balasubramanian; Sue Higham; Malee Fernando; Barney Harrison
Journal:  World J Surg       Date:  2011-09       Impact factor: 3.352

2.  Serum osteoprotegerin and future risk of cancer and cancer-related mortality in the general population: the Tromsø study.

Authors:  Anders Vik; Ellen E Brodin; Ellisiv B Mathiesen; Jan Brox; Lone Jørgensen; Inger Njølstad; Sigrid K Brækkan; John-Bjarne Hansen
Journal:  Eur J Epidemiol       Date:  2014-12-02       Impact factor: 8.082

Review 3.  Cytokines, inflammation and colon cancer.

Authors:  Lidija Klampfer
Journal:  Curr Cancer Drug Targets       Date:  2011-05       Impact factor: 3.428

Review 4.  Escaping cell death via TRAIL decoy receptors: a systematic review of their roles and expressions in colorectal cancer.

Authors:  Kelly Xue Jing Jong; Elsa Haniffah Mejia Mohamed; Zaridatul Aini Ibrahim
Journal:  Apoptosis       Date:  2022-10-07       Impact factor: 5.561

5.  Downregulation of osteoprotegerin expression in metastatic colorectal carcinoma predicts recurrent metastasis and poor prognosis.

Authors:  Ahrim Moon; Sung-Im Do; Hyun-Soo Kim; Youn-Wha Kim
Journal:  Oncotarget       Date:  2016-11-29

Review 6.  Colorectal Cancer and Bone Tissue: Fantastic Relations and Where to Find Them.

Authors:  Isabella Gigante; Valeria Tutino; Valentina De Nunzio; Maria Notarnicola
Journal:  Cancers (Basel)       Date:  2020-07-24       Impact factor: 6.639

7.  Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact.

Authors:  Penny E Reid; Nicola J Brown; Ingunn Holen
Journal:  Mol Cancer       Date:  2009-07-15       Impact factor: 27.401

8.  Down-regulation of osteoprotegerin expression as a novel biomarker for colorectal carcinoma.

Authors:  Hyun-Soo Kim; Gun Yoon; Sung-Im Do; Sung-Joo Kim; Youn-Wha Kim
Journal:  Oncotarget       Date:  2016-03-22

Review 9.  Osteoprotegerin rich tumor microenvironment: implications in breast cancer.

Authors:  Sudeshna Goswami; Neelam Sharma-Walia
Journal:  Oncotarget       Date:  2016-07-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.